Abnormal 5-HT1D receptor function in cluster headache: a neuroendocrine study with sumatriptan
Related Experiment Video
Updated: Sep 25, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
L Pinessi1, I Rainero, W Valfrè
1Neurology III, Headache Centre, Department of Neuroscience, Division of Endocrinology, Department of Internal Medicine and Division of Medicine, Department of Internal Medicine, University of Turin, Turin, Italy. lorenzo.pinessi@unito.it
Abstract:
The purpose of this study was to assess the sensitivity of 5-HT(1D) receptors in patients with episodic cluster headache using sumatriptan as a pharmacological probe. The drug, a selective 5-HT(1B/1D) agonist, stimulates the secretion of growth hormone and inhibits the release of prolactin, adrenocorticotropic hormone (ACTH) and cortisol. These effects may be used to explore the function of serotonergic systems in vivo. We administered subcutaneous sumatriptan and placebo to 20 patients with cluster headache (10 in the active phase and 10 in the remission period) and to 12 controls. The sumatriptan-induced increase of growth hormone concentrations was significantly (P < 0.05) blunted in patients with active cluster headache. Prolactin and ACTH responses to the drug were significantly (P < 0.05) reduced in patients with cluster headache, both in the active and in the remission period. Our results suggest that cerebral serotonergic functions mediated by 5-HT(1D) receptors are altered in patients with episodic cluster headache.
Related Concept Videos
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drugs Affecting Neurotransmitter Release or Uptake
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
G Protein-coupled Receptors

